Cost-Effectiveness and Long-Term Economic Value of Orca-T Therapy

Rawan Faramand, MD, presents a compelling cost analysis based on the Precision-T trial (NCT04013685), focusing on the economic implications of utilizing Orca-T compared to traditional graft-versus-host disease (GVHD) prophylaxis. The central finding of the analysis is that Orca-T offers a significant net monetary benefit, largely driven by its ability to reduce the incidence of chronic GVHD. Although the therapy requires an initial investment, the long-term reduction in medical complications leads to substantial savings in the back end of the patient’s care journey.

The study utilized a comprehensive economic model that factored in direct medical cost savings, such as reduced rehospitalizations and fewer treatments for chronic complications. Additionally, the analysis accounted for Quality-Adjusted Life Years (QALYs), which were notably improved in patients receiving Orca-T. By applying the standard US willingness-to-pay threshold of $150,000 for oncology treatments, researchers calculated a net monetary benefit of approximately $1.7 million when comparing Orca-T to the traditional tacrolimus and methotrexate regimen. This high value reflects the significant physical and financial toll that chronic GVHD places on the healthcare system and the patient.

The analysis also included a comparison against post-transplant cyclophosphamide (PTCy), which is currently considered a more effective standard than methotrexate-based regimens. When evaluated against PTCy, Orca-T still maintained a net monetary benefit of approximately $621,000. Although this margin is narrower than the comparison with older standards—partly because PTCy already offers improved GVHD rates—Orca-T continues to provide superior economic and clinical value. Faramand concludes that by investing in high-precision cell therapy upfront, healthcare providers can ultimately lower the total cost of care while simultaneously improving the survival and quality of life for transplant recipients.